Veracyte, Inc.(VCYT) Stock Research - Grey Stern Research

Veracyte, Inc. (VCYT) Stock Analysis

$42.84 (-2.84%)

VCYT Financial Performance


Use the table below to view Veracyte, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $42.84 -
52 Week Low $18.61 -
52 Week High $44.50 -
Market Cap $3.3 Billion 5/22
Gross Margin 68% 11/22
Profit Margin 13% 1/22
EBITDA margin 10% 1/22
Q2 - 2024 Revenue $115.9 Million 1/22
Q2 - 2024 Earnings $15.2 Million 1/22
Q2 - 2024 Free Cash Flow $27.7 Million 1/22
Trailing 4 Quarters Revenue $327.1 Million 1/22
Trailing 4 Quarters Earnings $19.0 Million 2/22
Quarterly Earnings Growth 280% 1/22
Annual Earnings Growth 175% 2/22
Quarterly Revenue Growth 28% 6/22
Annual Revenue Growth -3% 18/22
Cash On Hand $274.1 Million 6/22
Short Term Debt $7.3 Million 4/22
Long Term Debt $12.4 Million 14/22

Veracyte, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Veracyte, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 174.51 1/22
PS 10.15 14/22
PB 2.82 13/22
PC 12.11 9/22
Liabilities to Equity 0.08 18/22
ROA 0.01 2/22
ROE 0.02 3/22
Current Ratio 12.88 4/22
Quick Ratio 2.77 13/22
Long Term Debt to Equity 0.01 18/22
Debt to Equity 0.02 17/22
Burn Rate -21.35 21/22
Cash to Cap 0.08 14/22
CCR 1.83 1/22
EV to EBITDA 255.11 1/22
EV to Revenue 9.37 13/22

Company Details

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

CEO: Ms. Bonnie Anderson

Website: https://www.veracyte.com

Address: 6000 Shoreline Ct Ste 300 South San Francisco, CALIFORNIA

Exchange: NASDAQ Global Market

Industry: Biotechnology

Veracyte, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Veracyte, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Kura Oncology, Inc. KURA $832.8 Million
Solid Biosciences Inc. SLDB $198.2 Million
Protagonist Therapeutics, Inc. PTGX $2.5 Billion
AnaptysBio, Inc. ANAB $719.9 Million
uniQure N.V. QURE $321.2 Million
Enanta Pharmaceuticals, Inc. ENTA $169.8 Million
Syndax Pharmaceuticals, Inc. SNDX $1.4 Billion
Cytokinetics, Incorporated CYTK $5.9 Billion
Rocket Pharmaceuticals, Inc. RCKT $1.2 Billion
Merus N.V. MRUS $3.0 Billion
Rhythm Pharmaceuticals, Inc. RYTM $3.6 Billion
Crinetics Pharmaceuticals, Inc. CRNX $5.4 Billion
Homology Medicines, Inc. FIXX $3.0 Million
IDEAYA Biosciences, Inc. IDYA $2.3 Billion
MeiraGTx Holdings plc MGTX $470.5 Million
Replimune Group, Inc. REPL $983.2 Million
Keros Therapeutics, Inc. KROS $2.6 Billion
Cerevel Therapeutics Holdings, Inc. CERE $8.2 Billion
Viridian Therapeutics, Inc. VRDN $1.6 Billion
Icosavax, Inc. ICVX $769.0 Million
Ventyx Biosciences, Inc. VTYX $177.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
VCYT Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 115.9 Million $15.2 Million
Q1 2024 $ 114.4 Million $5.7 Million
Q4 2023 $ 96.8 Million -$1.9 Million
Q3 2023 $ 0 $0
Q2 2023 $ 90.3 Million -$8.4 Million
Q1 2023 $ 82.4 Million -$5.7 Million
Q4 2022 $ 80.3 Million -$3.8 Million
Q3 2022 $ 75.6 Million -$8.7 Million

View All

VCYT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $274.1 Million $1.3 Billion $19.7 Million $1.2 Billion
Q1 2024 $235.9 Million $1.2 Billion $20.7 Million $1.1 Billion
Q4 2023 $209.2 Million $1.2 Billion $14.0 Million $1.1 Billion
Q3 2023 $216.5 Million $1.1 Billion $12.6 Million $1.0 Billion
Q2 2023 $191.1 Million $1.2 Billion $14.9 Million $1.1 Billion
Q1 2023 $177.9 Million $1.2 Billion $13.8 Million $1.1 Billion
Q4 2022 $154.2 Million $1.2 Billion $14.7 Million $1.1 Billion
Q3 2022 $170.1 Million $1.1 Billion $16.7 Million $1.0 Billion

View All

VCYT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $27.7 Million -$2.2 Million $39.2 Million
Q1 2024 $26.8 Million -$2.8 Million $26.7 Million
Q4 2023 -$11.1 Million -$2.1 Million -$7.3 Million
Q3 2023 $7.6 Million $0 $7.6 Million
Q2 2023 $10.4 Million $0 $10.4 Million
Q1 2023 -$3.2 Million -$993,000 $23.6 Million
Q4 2022 $7.9 Million -$1.9 Million -$15.9 Million
Q3 2022 $5.3 Million -$1.7 Million $16.7 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions